Methotrexate Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. This reduces the availability of nucleotides needed for DNA, RNA and protein synthesis, thereby limiting the replication of rapidly dividing cells such as immune cells and cancer cells.

The specific dose of Methotrexate Accord is determined by the prescribing clinician based on the patient’s condition, age, weight, renal and hepatic function, and treatment goals. Dosage regimens vary widely across the approved indications.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Methotrexate is a folate antagonist, similar to drugs like pemetrexed and leflunomide, but it is distinguished by its broad indication range, including both autoimmune diseases and multiple cancers. Its dosing flexibility and extensive clinical experience make it a cornerstone therapy, though safety monitoring is more intensive than for some newer agents.

Methotrexate Accord should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging to maintain stability and prevent moisture exposure.

The product is supplied as a sterile injectable solution and can be given via intra‑arterial, intramuscular or intravenous routes, depending on the clinical indication and physician’s judgment. Administration is performed by qualified healthcare professionals in a controlled setting.

The most serious risks include bone‑marrow suppression leading to pancytopenia, severe hepatotoxicity or liver fibrosis, pulmonary toxicity such as interstitial pneumonitis, and acute renal failure. Prompt monitoring of blood counts, liver and kidney function is essential to detect these complications early.

Methotrexate Accord is contraindicated in pregnant women, patients with severe renal or hepatic impairment, and individuals with known hypersensitivity to methotrexate or any component of the formulation. It should also be avoided in patients receiving live vaccines.